Factory Supply High Quality Perindopril CAS 82834-16-0 Treatment of Hypertension

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: 82834-16-0
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Product Name: Perindopril
• CAS: 82834-16-0
• Mf: C19h32n2o5
• Appearance: White
• Assay: >99%
• Expiration Date: 2 Years
• Transport Package: Dry and Cool
• Specification: 1kg/Aluminum Foil Bag, 25kg/Cardboard Drum
• Trademark: Gina
• Origin: Shaanxi, China
• Production Capacity: 100000 Kilogram/ Month

Product Description

Perindopril is a third-generation angiotensin-converting enzyme inhibitor, and its antihypertensive effect reaches the maximum after 6 hours of administration, and the effect lasts for a long time. Pertipril can expand large and small arteries, reduce blood volume, reduce systemic vascular resistance, left ventricular filling pressure and pulmonary capillary wedge pressure, increase cardiac output and stroke volume, increase cardiac index without changing heart rate, Improve exercise tolerance, reduce left ventricular hypertrophy, and improve hemodynamics. This product is well tolerated, does not cause hyperglycemia, and has no adverse effects on blood lipids. After taking perindopril, the onset of ACE inhibition is slower than that of other ACE inhibitors, and the inhibition rate of ACE is more than 90%.
 

1. Perindopril Erbumine for the treatment of hypertension, congestive heart failure and other conditions
2. Perindopriltert-buty laminesalt, chemically known as (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid tert-buty lamine salt, was developed by the French company Servier as an angiotensin-converting enzyme inhibitor. It is an angiotensin-converting enzyme inhibitor developed by Servier and marketed in France in 1989. It is used clinically for the treatment of hypertension and congestive heart failure because it has a dilating and elastic repair effect on the arterial vasculature, reduces left ventricular hypertrophy, corrects myocardial hypertrophy and subendocardial collagen excess, and reduces the incidence of perfusion arrhythmias.